NewcelX AG has announced positive results from an international collaborative research study exploring advanced biomaterial approaches for the delivery of stem cell-derived islets in the treatment of Type 1 Diabetes. The study focused on combining stem cell biology with innovative delivery and immune protection strategies, aiming to achieve functional insulin secretion without the need for systemic immunosuppression. Results from the study have already been reported and contribute to the ongoing development of NewcelX’s investigational therapy, IsletRx. The research was supported by the Australian Foundation for Diabetes Research, the National Stem Cell Foundation of Australia, and Breakthrough T1D.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN60864) on January 12, 2026, and is solely responsible for the information contained therein.